• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation.一名合并B细胞淋巴瘤的COVID-19患者通过联合使用阿育吠陀配方药物进行治疗。
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100632. doi: 10.1016/j.jaim.2022.100632. Epub 2022 Aug 12.
2
Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial.玛德哈夫拉沙扬补剂作为中度新冠肺炎患者辅助治疗药物的疗效:随机对照试验的初步结果
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100590. doi: 10.1016/j.jaim.2022.100590. Epub 2022 May 24.
3
A pilot clinical study of an add-on Ayurvedic formulation containing and in mild to moderate COVID-19.一项针对轻度至中度新冠肺炎患者的、添加含有[具体成分1]和[具体成分2]的阿育吠陀配方药物的试点临床研究。 (注:原文中“containing and ”处具体成分缺失)
J Ayurveda Integr Med. 2022 Apr-Jun;13(2):100454. doi: 10.1016/j.jaim.2021.05.008. Epub 2021 Jun 10.
4
Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial.草药提取物对 COVID-19 轻症至中度患者恢复呼吸健康和改善先天免疫安全性和疗效的研究:一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Nov 23;21(1):943. doi: 10.1186/s13063-020-04906-x.
5
The use of integrative therapy based on Yoga and Ayurveda in the treatment of a high-risk case of COVID-19/SARS-CoV-2 with multiple comorbidities: a case report.基于瑜伽和阿育吠陀的整合疗法在 COVID-19/SARS-CoV-2 合并多种合并症高危病例治疗中的应用:病例报告。
J Med Case Rep. 2021 Feb 24;15(1):95. doi: 10.1186/s13256-020-02624-1.
6
Standalone Ayurvedic treatment of high-risk COVID-19 patients with multiple co-morbidities: A case series.针对患有多种合并症的高危COVID-19患者的阿育吠陀单独治疗:病例系列
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100466. doi: 10.1016/j.jaim.2021.06.006. Epub 2021 Jun 17.
7
Integrative management of critical case of Covid 19 with and modern medicine: A case report.中西医结合治疗新型冠状病毒肺炎危重症病例报告
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100496. doi: 10.1016/j.jaim.2021.07.012. Epub 2021 Jul 28.
8
Metabolite profiling and evaluation of CYP450 interaction potential of 'Trimada'- an Ayurvedic formulation.代谢产物分析及“Trimada”-一种阿育吠陀制剂的 CYP450 相互作用潜力评估。
J Ethnopharmacol. 2021 Feb 10;266:113457. doi: 10.1016/j.jep.2020.113457. Epub 2020 Oct 9.
9
Ayurvedic treatment of COVID-19: A case report.阿育吠陀疗法治疗新冠肺炎:一例病例报告。
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100329. doi: 10.1016/j.jaim.2020.06.001. Epub 2020 Jun 19.
10
Ayurvedic management of persistent hypoxia in a diabetic and hypertensive COVID-19 patient in the post-hospitalization period-A case report.糖尿病和高血压COVID-19患者出院后持续性缺氧的阿育吠陀疗法——病例报告
J Ayurveda Integr Med. 2022 Apr-Jun;13(2):100509. doi: 10.1016/j.jaim.2021.08.002. Epub 2021 Aug 7.

本文引用的文献

1
Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial.玛德哈夫拉沙扬补剂作为中度新冠肺炎患者辅助治疗药物的疗效:随机对照试验的初步结果
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100590. doi: 10.1016/j.jaim.2022.100590. Epub 2022 May 24.
2
Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis.癌症诊断对 COVID-19 患者结局的影响:系统评价和荟萃分析。
BMJ Open. 2022 Feb 7;12(2):e044661. doi: 10.1136/bmjopen-2020-044661.
3
Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease.甘草酸通过抑制病毒主蛋白酶有效抑制 SARS-CoV-2 复制。
Viruses. 2021 Apr 2;13(4):609. doi: 10.3390/v13040609.
4
Ayurveda co-interventions have supported complete recovery in severe COVID-19 infection with a chest severity score 18/25: A case report.阿育吠陀辅助干预措施助力胸部严重程度评分为18/25的重症新冠肺炎感染患者实现完全康复:一例病例报告。
J Ayurveda Integr Med. 2022 Apr-Jun;13(2):100417. doi: 10.1016/j.jaim.2021.02.008. Epub 2021 Mar 12.
5
Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants.癌症对 COVID-19 患者的影响:一项纳入 63019 名参与者的系统评价和荟萃分析。
Cancer Biol Med. 2021 Feb 15;18(1):298-307. doi: 10.20892/j.issn.2095-3941.2020.0559.
6
Pathophysiology of Covid-19 and host centric approaches in .新冠病毒病的病理生理学及以宿主为中心的方法
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100380. doi: 10.1016/j.jaim.2020.11.010. Epub 2020 Dec 2.
7
Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study.新冠病毒肺炎合并淋巴瘤住院患者的预后决定因素:一项回顾性多中心队列研究。
EClinicalMedicine. 2020 Oct;27:100549. doi: 10.1016/j.eclinm.2020.100549. Epub 2020 Oct 13.
8
The role of dysregulated immune responses in COVID-19 pathogenesis.免疫应答失调在 COVID-19 发病机制中的作用。
Virus Res. 2020 Dec;290:198197. doi: 10.1016/j.virusres.2020.198197. Epub 2020 Oct 16.
9
The Risk and Prognosis of COVID-19 Infection in Cancer Patients: A Systematic Review and Meta-Analysis.癌症患者感染 COVID-19 的风险和预后:系统评价和荟萃分析。
Hematol Oncol Stem Cell Ther. 2022 Jun 1;15(2):45-53. doi: 10.1016/j.hemonc.2020.07.005.
10
Ayurvedic clinical profile of COVID-19 - A preliminary report.COVID-19的阿育吠陀临床概况——初步报告。
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100326. doi: 10.1016/j.jaim.2020.05.011. Epub 2020 Jun 12.

一名合并B细胞淋巴瘤的COVID-19患者通过联合使用阿育吠陀配方药物进行治疗。

COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation.

作者信息

Dilip Pandkar Prasad, Deshmukh Santosh Raosaheb, Sachdeva Vinay

机构信息

Department of Kriya sharir (Ayurveda Physiology), Bharati Vidyapeeth Deemed University, College of Ayurveda, Pune, 411043, India.

Shri Vishwavati Ayurvedic Chikitsalay and Research Centre, Kolhapur, Maharashtra, India.

出版信息

J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100632. doi: 10.1016/j.jaim.2022.100632. Epub 2022 Aug 12.

DOI:10.1016/j.jaim.2022.100632
PMID:35975131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9372187/
Abstract

'Renaissance took place in Chaos and plague'. It was COVID-19 pandemic, when world realized ayurveda co-interventions are praiseworthy even in acute, infective and fatal conditions like COVID-19. We report perhaps first case of COVID-19 patient with cancer managed with poly-herbal ayurvedic formulation and integrated approach. In the first wave of COVID-19 (June 2020), a 47 year old male with history of Chronic kidney disease and active B Cell Lymphoma complained of fever, malaise, cattarah and ageusia. He was found positive on RT-PCR which was done promptly and was later treated in home quarantine with antipyretics, Vitamin C and Madhav rasayan a polyherbal preparation containing , , , , and designed to modulate host response. It was challenging to treat a patient with cancer with immunocompromised status as he had recently finished his chemotherapy cycle (R-CHOP regimen). Patient well tolerated the intervention and recovered symptomatically. He did not developed any respiratory complications and oxygen saturation remained maintained. On 7th day RT-PCR was found to be negative. Plethora of literature is available on anti-viral and immunomodulatory efficacies of Ayurveda herbs based on in vitro studies. Such efficacies can be replicated at patient's level if supported with wisdom of Ayurveda epistemology. Early diagnosis on RT-PCR and early inception of ayurveda medicine and diet interventions might be crucial element for better recovery.

摘要

“复兴在混乱和瘟疫中发生”。正是在新冠疫情期间,全世界意识到阿育吠陀辅助干预措施即使在像新冠这样的急性、感染性和致命疾病中也值得称赞。我们报告了或许首例采用多草药阿育吠陀配方和综合方法治疗的新冠合并癌症患者。在新冠疫情的第一波(2020年6月)中,一名患有慢性肾病且患有活跃B细胞淋巴瘤的47岁男性出现发热、不适、卡他症状和味觉丧失。他的逆转录聚合酶链反应(RT-PCR)检测呈阳性,检测迅速进行,随后在家中隔离,接受退烧药、维生素C和玛德哈夫拉萨扬(Madhav rasayan)治疗,玛德哈夫拉萨扬是一种多草药制剂,含有[此处原文缺失部分草药名称],旨在调节宿主反应。治疗一名处于免疫功能低下状态的癌症患者具有挑战性,因为他最近刚完成化疗周期(R-CHOP方案)。患者对干预措施耐受性良好,症状得到缓解。他没有出现任何呼吸道并发症,血氧饱和度保持稳定。在第7天,RT-PCR检测结果为阴性。基于体外研究,有大量关于阿育吠陀草药抗病毒和免疫调节功效的文献。如果有阿育吠陀认识论的智慧支持,这些功效可以在患者层面得到复制。RT-PCR早期诊断以及阿育吠陀药物和饮食干预的早期启动可能是更好康复的关键因素。